Support - Research - Education

Back to top

Research & Genetics

Unfortunately, there is no cure for CLOVES. Surgery and other types of medical interventions are the only treatments for CLOVES overgrowth, vascular anomalies and other related medical issues.


New Research Opportunity [6-5-19]
ArQule is currently conducting the MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) clinical trial for patients who have been diagnosed with either Proteus syndrome (PS), which involves a mutation in the AKT gene, or those who have been diagnosed with one of a number of distinct overgrowth disorders characterized by a mutation in the PIK3CA gene, referred to as PIK3CA-related overgrowth spectrum (PROS). There are currently no approved medicinal treatments for PS and PROS, leaving patients with minimal treatment options.

The MOSAIC trial aims to determine whether miransertib, a drug which inhibits the biological pathway that both AKT and PIK3CA mutations affect, can effectively treat patients who suffer from overgrowth syndromes associated with these mutations.

Based on the mechanism of action of miransertib, trial participants must have a mutation in either the AKT1 or PIK3CA gene to be eligible to participate in the MOSAIC trial. Learn more about how miransertib works below.

For more information, please visit our Clinical Trial page  or email ArQule at 

Additional information about the MOSAIC trial can be found here.


New Research Opportunity [6-13-18]
A medical first: CLOVES Syndrome and overgrowth syndromes:remarkable improvement in the health of 19 pediatric and adult patients using a new therapeutic strategy called Alpelisib BYL719. Dr. Guillaume Canaud at the Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, Inserm (INEM Institute Necker Enfants Malades – Centre for Molecular Medicine) and his team recently demonstrated the efficacy of a novel medication, a specific inhibitor called BYL719, in a cohort of 19 patients treated at the Necker-Enfants Malades Hospital – AP-HP and suffering from CLOVES Syndrome (Congenital Lipomatous Overgrowth, Vascular Malformation, Epidermal Naevi) or similar disorders.  

Press Release about Dr. Canaud's research

Link to stay up to date on Dr. Canaud's research   (use google Chrome to translate if need be)


The NIH created this visual for us, to help explain PIK3ca mutations and overgrowth. [March 20, 2017]
Image to explain PIK3ca mutations in CLOVES and overgrowth conditions

Boston Children's Hospital - Sirolimus

As of January 2017, there is no open study of a medication to treat CLOVES. There is growing experience using sirolimus to manage some symptoms and complications of CLOVES,  based on studies done  by Drs. Denise Adams and Cameron Trenor at Boston Children’s Hospital. Sirolimus has been most effective at controlling infections, leaking from lymphatic vesicles, bleeding and enlarging vascular masses. The decision to recommend sirolimus is based on an individual patient’s complications and should be considered with your physician.


NIH Ongoing Research for PIK3ca mutations:

The National Institutes of Health does research testing of patients with all kinds of overgrowth.

If you'd like to learn more, contact Anna Buser at  or by phone at 301-435-6689.

More information here

NIH Study Data (March 2015)   :   Responses to survey created by the National Institutes of Health from June 2014 - March 2015


Research at Boston Children's Hospital (ongoing)
Dr. Matthew Warman of Boston Children's Hospital are continuing to do research based gene sequencing for people with CLOVES. In addition, Dr. Warman's lab has mouse models with the PIK3ca mutation. The mouse models will allow researchers to learn about these disorders and to test therapies that may prevent, delay or reverse the consequences of the genetic mutation.


Opportunity for CLOVES Research (ongoing)
CLOVES Registry Recruitment Flyer


July 2014 --- Clinical Genetic Test available via Washington University 
This test must be ordered by a geneticist/physician. This is somatic variant analysis by next-generation sequencing for Segmental Overgrowth, McCune Albright (SOMA) and related syndromes. The test includes concise, expert interpretations by board-certified clinical genomicists and is covered by most insurance.


Segmental Overgrowth Study (Cambridge, UK)
The SOS are a group of scientists and doctors based in Cambridge, United Kingdom and study CLOVES and related conditions featuring overgrowth of one part of the body, and normal growth elsewhere. As part of our research study we are able to screen genes that are known to cause CLOVES and thereby offer a genetic diagnosis. 

For more information:


April 23, 2013 --- Research Opportunity with National Institutes of Health (NIH)
Announcement from CLOVES Syndrome Community
Letter from National Institues of Health
Questions and Answers about research with NIH


CLOVES Gene Mutation Discovery (5/31/12)
Researchers at Boston Children's Hospital identify a genetic cause for CLOVES

Share this